Reduction of antibiotic treatment initiation events by replacing regular textiles with biocidal copper oxide impregnated textiles: crossover, double blind and placebo controlled clinical study

Reduction of antibiotic treatment initiation events by replacing regular textiles with biocidal copper oxide impregnated textiles: crossover, double blind and placebo controlled clinical study - Reduction of nosocomial infection by using copper impregnated textiles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021723

Enrollment

Registered

2016-03-31

Start date

2015-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prevention of nosocomial infections in long term care facilities

Interventions

A double-blind cross-over study. During period I, one ward received copper oxide impregnated textiles (linen, patients clothes and towels), and the other received Control untreated textiles

in period III the ward that received the treated textiles received the control textiles and vis versa. During Period II both wards received usual textiles. The textiles were coded with different color

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients in the wards

Exclusion criteria

Exclusion criteria: no exclusion

Design outcomes

Primary

Measure	Time frame
Antibiotic treatment initiation (ATI) events: a clinical presentation in which it was decided to administer antimicrobial therapy per 1000 hospitalization days during the study periods.	—

Secondary

Measure	Time frame
fever days: number of days during which the axillary temperature was above 37.6C per 1000 hospitalization days during the study periods. Antibiotic usage: the number of days antibiotics were administrated per 1000 hospitalization days. The antibiotics defined daily dose (DDD) per 1000 patient days was calculated according to the WHO Collaborating Center for Drug Statistics Methodology guidelines, during the study periods.	—

Measure

Time frame

fever days: number of days during which the axillary temperature was above 37.6C per 1000 hospitalization days during the study periods. Antibiotic usage: the number of days antibiotics were administrated per 1000 hospitalization days. The antibiotics defined daily dose (DDD) per 1000 patient days was calculated according to the WHO Collaborating Center for Drug Statistics Methodology guidelines, during the study periods.

—

Countries

Asia(except Japan)

Contacts

Public ContactDr. Gadi Borkow

Cupron Inc. Cupron Scientific

gadi@cupron.com972-546611287

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026